410 related articles for article (PubMed ID: 30916367)
1. Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells.
Chen Q; Hu Q; Dukhovlinova E; Chen G; Ahn S; Wang C; Ogunnaike EA; Ligler FS; Dotti G; Gu Z
Adv Mater; 2019 Jun; 31(23):e1900192. PubMed ID: 30916367
[TBL] [Abstract][Full Text] [Related]
2. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
[TBL] [Abstract][Full Text] [Related]
3. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.
Leuci V; Donini C; Grignani G; Rotolo R; Mesiano G; Fiorino E; Gammaitoni L; D'Ambrosio L; Merlini A; Landoni E; Medico E; Capellero S; Giraudo L; Cattaneo G; Iaia I; Pignochino Y; Basiricò M; Vigna E; Pisacane A; Fagioli F; Ferrone S; Aglietta M; Dotti G; Sangiolo D
Clin Cancer Res; 2020 Dec; 26(23):6321-6334. PubMed ID: 32900797
[TBL] [Abstract][Full Text] [Related]
4. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
5. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
7. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L; Cattaneo G; Gammaitoni L; Iaia I; Donini C; Massa A; Centomo ML; Basiricò M; Vigna E; Pisacane A; Picciotto F; Berrino E; Marchiò C; Merlini A; Paruzzo L; Poletto S; Caravelli D; Biolato AM; Bortolot V; Landoni E; Ventin M; Ferrone CR; Aglietta M; Dotti G; Leuci V; Carnevale-Schianca F; Sangiolo D
J Exp Clin Cancer Res; 2023 Nov; 42(1):310. PubMed ID: 37993874
[TBL] [Abstract][Full Text] [Related]
8. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
[TBL] [Abstract][Full Text] [Related]
9. Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma.
Teppert K; Winter N; Herbel V; Brandes C; Lennartz S; Engert F; Kaiser A; Schaser T; Lock D
Front Immunol; 2023; 14():1178060. PubMed ID: 37901209
[TBL] [Abstract][Full Text] [Related]
10. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
11. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy.
Chen Z; Pan H; Luo Y; Yin T; Zhang B; Liao J; Wang M; Tang X; Huang G; Deng G; Zheng M; Cai L
Small; 2021 Apr; 17(14):e2007494. PubMed ID: 33711191
[TBL] [Abstract][Full Text] [Related]
12. NIR-Light-Triggered Anticancer Strategy for Dual-Modality Imaging-Guided Combination Therapy via a Bioinspired Hybrid PLGA Nanoplatform.
Shen X; Li T; Chen Z; Xie X; Zhang H; Feng Y; Li S; Qin X; Yang H; Wu C; Zheng C; Zhu J; You F; Liu Y
Mol Pharm; 2019 Mar; 16(3):1367-1384. PubMed ID: 30776896
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
14. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
Harrer DC; Dörrie J; Schaft N
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
[TBL] [Abstract][Full Text] [Related]
15. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
16. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma.
Shi B; Li D; Yao W; Wang W; Jiang J; Wang R; Yan F; Liu H; Zhang H; Ye J
Biomater Sci; 2022 May; 10(10):2577-2589. PubMed ID: 35393988
[TBL] [Abstract][Full Text] [Related]
19. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
20. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
Harrer DC; Schuler G; Dörrie J; Schaft N
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
